NCT02343094View on ClinicalTrials.gov

Phenylbutyrate in Proteinuric Nephropathies

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

July 31, 2016

Conditions
Proteinuric Diseases
Interventions
DRUG

PBA 7,5g/d

Treatment for 14 days with PBA

DRUG

PBA 15g/d

Treatment for 14 days with PBA

Trial Locations (1)

75015

Hôpital Necker Enfants Malades, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT02343094 - Phenylbutyrate in Proteinuric Nephropathies | Biotech Hunter | Biotech Hunter